OBJECTIVE: To observe the hypotensive effects of Qindan Capsule (QC) on spontaneous hypertensive rats (SHR) and its effect on the contents of endothelin (ET), calcitonin gene-related peptide (CGRP) and angiotensin-II (Ang-II ) in plasma and vascular tissues, and to investigate the possible mechanism of QC in lowering blood pressure. METHODS: Forty SHRs were divided into 5 groups: the high dosage QC group [QCHD, 750 mg/(kgxd)], the low dosage QC group [QCLD, 150 mg/(kgxd) ], the Niuhuang Jiangya Pill group [NJP, 200 mg/(kgxd) ], the Captopril group [ 15 mg/(kg d) land the model group, 8 in each group. Meanwhile, a normal control group consisting of 8 Wistar-Kyoto (WKY) rats was set up also. All the rats were administered with medicine through gastrogavage. Systolic blood pressure (SBP), level of ET, CGRP and Ang-II in plasma and Ang-II in tissues of mesenteric artery were detected in all the rats after 12 weeks of treatment. RESULTS: The level of SBP after treatment in the QCHD group was lower than that in the model group (P<0.01), but with no significant difference as compared with that in the Captopril group and the NJP group (P>0.05). After treatment, the plasma level of ET was lower and CGRP higher than those in the model group (both P<0.05), and also higher than those in the NJP and Captopril group (both P<0.05). As for the content of Ang-II , in mesenteric arterial tissues, it was lower in the QCHD group than that in the model group ( P<0.05), but in plasma, it showed no significant difference between the two groups (P>0.05). CONCLUSION: QC has a satisfactory hypotensive action on SHR rats, and its mechanism may be associated with the regulation on plasma vasoactive peptide and regional renin-angiotensin system.
OBJECTIVE: To observe the hypotensive effects of Qindan Capsule (QC) on spontaneous hypertensive rats (SHR) and its effect on the contents of endothelin (ET), calcitonin gene-related peptide (CGRP) and angiotensin-II (Ang-II ) in plasma and vascular tissues, and to investigate the possible mechanism of QC in lowering blood pressure. METHODS: Forty SHRs were divided into 5 groups: the high dosage QC group [QCHD, 750 mg/(kgxd)], the low dosage QC group [QCLD, 150 mg/(kgxd) ], the Niuhuang Jiangya Pill group [NJP, 200 mg/(kgxd) ], the Captopril group [ 15 mg/(kg d) land the model group, 8 in each group. Meanwhile, a normal control group consisting of 8 Wistar-Kyoto (WKY) rats was set up also. All the rats were administered with medicine through gastrogavage. Systolic blood pressure (SBP), level of ET, CGRP and Ang-II in plasma and Ang-II in tissues of mesenteric artery were detected in all the rats after 12 weeks of treatment. RESULTS: The level of SBP after treatment in the QCHD group was lower than that in the model group (P<0.01), but with no significant difference as compared with that in the Captopril group and the NJP group (P>0.05). After treatment, the plasma level of ET was lower and CGRP higher than those in the model group (both P<0.05), and also higher than those in the NJP and Captopril group (both P<0.05). As for the content of Ang-II , in mesenteric arterial tissues, it was lower in the QCHD group than that in the model group ( P<0.05), but in plasma, it showed no significant difference between the two groups (P>0.05). CONCLUSION: QC has a satisfactory hypotensive action on SHR rats, and its mechanism may be associated with the regulation on plasma vasoactive peptide and regional renin-angiotensin system.
Authors: Y Oh-hashi; T Shindo; Y Kurihara; T Imai; Y Wang; H Morita; Y Imai; Y Kayaba; H Nishimatsu; Y Suematsu; Y Hirata; Y Yazaki; R Nagai; T Kuwaki; H Kurihara Journal: Circ Res Date: 2001-11-23 Impact factor: 17.367
Authors: Gian Paolo Rossi; Martina Cavallin; Anna S Belloni; Giuseppina Mazzocchi; Gastone G Nussdorfer; Achille C Pessina; Saverio Sartore Journal: Cardiovasc Res Date: 2002-07 Impact factor: 10.787
Authors: Wenwu Bai; Min Ren; Wen Cheng; Xiaoting Lu; Deshan Liu; Bo Wang Journal: Evid Based Complement Alternat Med Date: 2021-04-28 Impact factor: 2.629